SIRT6 Antibody (6C9-D10-D3): sc-517556
- SIRT6 Antibody (6C9-D10-D3) is a mouse monoclonal IgG, cited in 5 publications, provided at 100 µg/ml
- raised against recombinant SIRT6 protein fragments of human origin
- recommended for detection of SIRT6 of mouse, rat and human origin by WB, IF and IHC(P)
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for SIRT6 Antibody (6C9-D10-D3). This work is in progress.
SIRT6 Antibody (6C9-D10-D3) is a mouse monoclonal IgG antibody that detects SIRT6 in mouse, rat, and human samples through applications such as western blotting (WB), immunofluorescence (IF), and immunohistochemistry. SIRT6, also known as SIR2L6, is a 355 amino acid protein that plays a crucial role in cellular processes by functioning as an NAD+-dependent histone H3 lysine 9 (H3K9) deacetylase. This enzymatic activity is vital for modulating telomeric chromatin, which influences DNA repair mechanisms and contributes to telomeric longevity, thereby impacting cellular aging and genomic stability. Nuclear localization of SIRT6 allows direct interaction with chromatin, facilitating regulation of gene expression and maintenance of telomere integrity. Additionally, SIRT6 binds zinc as a cofactor and exists in four isoforms due to alternative splicing, providing functional diversity and regulatory mechanisms in various biological contexts. With an ability to modulate critical cellular functions, anti-SIRT6 antibody (6C9-D10-D3) serves as an essential tool for researchers studying genomic stability and lifespan regulation.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
SIRT6 Antibody (6C9-D10-D3) References:
- LINE1 Derepression in Aged Wild-Type and SIRT6-Deficient Mice Drives Inflammation. | Simon, M., et al. 2019. Cell Metab. 29: 871-885.e5. PMID: 30853213
- Overexpression of Sirt6 promotes M2 macrophage transformation, alleviating renal injury in diabetic nephropathy. | Ji, L., et al. 2019. Int J Oncol. 55: 103-115. PMID: 31115579
- A novel SIRT6 activator ameliorates neuroinflammation and ischemic brain injury via EZH2/FOXC1 axis. | He, T., et al. 2021. Acta Pharm Sin B. 11: 708-726. PMID: 33777677
- Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling. | Peng, K., et al. 2023. Acta Pharm Sin B. 13: 2680-2700. PMID: 37425037
- SIRT6 deficiency in endothelial cells exacerbates oxidative stress by enhancing HIF1α accumulation and H3K9 acetylation at the Ero1α promoter. | Guo, Z., et al. 2023. Clin Transl Med. 13: e1377. PMID: 37598403
- SIRT6 pharmacological inhibition delays skin cancer progression in the squamous cell carcinoma. | Abbotto, E., et al. 2023. Biomed Pharmacother. 166: 115326. PMID: 37611438
- SIRT6's function in controlling the metabolism of lipids and glucose in diabetic nephropathy. | Wang, Y., et al. 2023. Front Endocrinol (Lausanne). 14: 1244705. PMID: 37876546
- The many faces of SIRT6 in the retina and retinal pigment epithelium. | Cheng, J., et al. 2023. Front Cell Dev Biol. 11: 1244765. PMID: 38016059
- Sirt6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma. | Xia, F., et al. 2024. Mol Ther. 32: 1760-1778. PMID: 38659223
- Sirt6 overexpression relieves ferroptosis and delays the progression of diabetic nephropathy via Nrf2/GPX4 pathway. | Du, L., et al. 2024. Ren Fail. 46: 2377785. PMID: 39082470
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SIRT6 Antibody (6C9-D10-D3) | sc-517556 | 100 µg/ml | $316.00 |